Treatment of gestational trophoblastic disease in the 2020s
- 15 December 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 33 (1) , 7-12
Abstract
Purpose of review: This review demonstrates the evidence for new systemic anticancer treatments and how they integrate within conventional management for gestational trophoblastic neoplasia (GTN). We present the evidence on atypical placental site nodules, and how they incorporate within the GTN spectrum, as well as updates regarding GTN staging and follow-up. Recent findings: First-line treatment for GTN still lies in conventional chemotherapy, although the introduction of anti-PD1/PD-L1 immune checkpoint inhibitors has shown significant promise in management of relapsed disease, with responses reported in multiple relapsed choriocarcinomas as well as epithelioid trophoblastic tumours and placental site trophoblastic tumours (ETT/PSTT). Following completion of treatment, ETT/PSTT still require life-long surveillance but for other GTN, no recurrences have been detected after 7 years. Summary: Checkpoint inhibitors are likely to play an increasing role in the future management of GTN management. Further refinement of prognostic factors to identify those most at risk of GTN recurrence is warranted so that surveillance can be focussed on those most at risk, whilst minimizing unnecessary intervention for those at lower risk.Keywords
This publication has 42 references indexed in Scilit:
- Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- EMA/CO for High-Risk Gestational Trophoblastic Neoplasia: Good Outcomes With Induction Low-Dose Etoposide-Cisplatin and Genetic AnalysisJournal of Clinical Oncology, 2013
- Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasiaGynecologic Oncology, 2012
- Gestational trophoblastic disease II: classification and management of gestational trophoblastic neoplasiaAmerican Journal of Obstetrics and Gynecology, 2011
- Gestational trophoblastic disease I: epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform moleAmerican Journal of Obstetrics and Gynecology, 2010
- Gestational trophoblastic diseaseThe Lancet, 2010
- Placental site trophoblastic tumor: lymphatic spread and possible target markersGynecologic Oncology, 2010
- Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasiasAnnals of Oncology, 2010
- Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE)Annals of Oncology, 2008
- A comparison of patients with relapsed and chemo-refractory gestational trophoblastic neoplasiaBritish Journal of Cancer, 2007